-

Hologic to Webcast Presentations at Upcoming Investor Conferences

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:

Hologic to Webcast Presentations at Upcoming Investor Conferences

Share
  • The 2025 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 20 at 9:30 a.m. Eastern Time (ET) in New York.
  • William Blair’s 45th Annual Growth Stock Conference in Chicago on Wednesday, June 4 at 4 p.m. Central Time
  • The Jefferies Global Healthcare Conference 2025 in New York on Thursday, June 5 at 11:05 a.m. ET

Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcasts will be available for 30 days following each event.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

SOURCE: Hologic, Inc.

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Industry:

Hologic, Inc.

NASDAQ:HOLX
Release Summary
Hologic to Webcast Presentations at Upcoming Investor Conferences
Release Versions
English
$Cashtags
$HOLX
Hashtags
#holx
#presentation

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Social Media Profiles
Hologic Facebook
Hologic Instagram
Hologic LinkedIN
Hologic Twitter
Hologic YouTube
More News From Hologic, Inc.

CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. announced today that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. Cervical cancer is the fourth most common cancer in women but is largely preventable through HPV vaccination and regular screening.1 Evidence shows that organized screening and early detection reduces deaths from cervical cancer...

Hologic’s New Sustainability Report Marks 40 Years of Impact

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc., a global leader in women’s health, today released its 2025 Sustainability Report. The new report coincides with Hologic’s 40th anniversary and underscores how the company’s longstanding purpose — to enable healthier lives for women everywhere, every day — continues to drive progress for patients, communities and the planet. “We have always firmly believed that our success as a company is fundamentally tied to our ability and commitment to help...

Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens’ latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, F...
Back to Newsroom